Cargando…

肺癌患者围手术期预防性抗凝的临床价值分析

BACKGROUND AND OBJECTIVE: The incidence of pulmonary embolism (PE) in lung cancer patients who underwent surgery increased during the perioperative period, and prophylactic anticoagulation therapy was important part of enhanced recovery after surgery (ERAS). However, the timing of preventive anticoa...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189024/
https://www.ncbi.nlm.nih.gov/pubmed/30309428
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.06
_version_ 1783363282902450176
collection PubMed
description BACKGROUND AND OBJECTIVE: The incidence of pulmonary embolism (PE) in lung cancer patients who underwent surgery increased during the perioperative period, and prophylactic anticoagulation therapy was important part of enhanced recovery after surgery (ERAS). However, the timing of preventive anticoagulation in patients with lung cancer remained controversial. This study was designed to investigate the safety and efficacy of perioperative prophylactic anticoagulation therapy for lung cancer patients. METHODS: Retrospective research was conducted on 562 lung cancer patients who underwent video-assisted thoracoscopic (VATS) anatomic pulmonary resections in West China Hospital from June 2016 to December 2016. 56 patients were treated with low molecular weight heparin (LMWH) anticoagulation 12 hours before operation until discharge, while the other 506 patients were treated with LMWH 24 hours after operation until discharge. The postoperative chest drainage volume, postoperative bleeding, pulmonary embolism incidence, and respiratory complications were analyzed. RESULTS: (1) There were no significant differences in prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) between the pre-operation prophylactic anticoagulation group (PRE group) [(11.5±3.9) s, (27.8±3.5) s, (0.96±0.06) s] and the post-operation prophylactic anticoagulation group (POST group) [(11.4±1.4) s, (28.3±4.0) s, (0.98±0.07) s] (P=0.796, P=0.250, P=0.137), and there was no significant difference in Caprini score between the PRE group (3.1±1.8) and the POST group (3.3±1.5) (P=0.104). (2) There were no significant differences in anesthesia time and intraoperative bleeding between PRE group [(130.2±53.9) min, (76.8±49.3) mL] and POST group [(142.2±56.5) min, (73.7±41.6) mL] (P=0.067, P=0.201). (3) The total drainage volume in 72 hours after operation in PRE group [(728.1±505.7) mL] was significantly higher than that of POST group [(596.4±373.5) mL] (P=0.005), while there were no significant differences between the two groups in total postoperative drainage volume [(1, 066.8±1, 314.6) mL vs (907.8±999.8) mL, P=0.203]. (4) There were no significant differences between the two groups in pulmonary embolism incidence (1.785% vs 0.019%, P=0.525) and postoperative bleeding rates (1.785% vs 0.039%, P=0.300). (5) There were no significant differences between PRE group and POST group in subcutaneous emphysema incidence (1.785% vs 1.581%, P=0.989) and pulmonary infection rates (14.285% vs 6.324%, P=0.085). CONCLUSION: The clinical value of preoperative prophylactic anticoagulation is equal to postoperative prophylactic anticoagulation for lung cancer patients.
format Online
Article
Text
id pubmed-6189024
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-61890242018-11-02 肺癌患者围手术期预防性抗凝的临床价值分析 Zhongguo Fei Ai Za Zhi 胸外科围术期vte专题 BACKGROUND AND OBJECTIVE: The incidence of pulmonary embolism (PE) in lung cancer patients who underwent surgery increased during the perioperative period, and prophylactic anticoagulation therapy was important part of enhanced recovery after surgery (ERAS). However, the timing of preventive anticoagulation in patients with lung cancer remained controversial. This study was designed to investigate the safety and efficacy of perioperative prophylactic anticoagulation therapy for lung cancer patients. METHODS: Retrospective research was conducted on 562 lung cancer patients who underwent video-assisted thoracoscopic (VATS) anatomic pulmonary resections in West China Hospital from June 2016 to December 2016. 56 patients were treated with low molecular weight heparin (LMWH) anticoagulation 12 hours before operation until discharge, while the other 506 patients were treated with LMWH 24 hours after operation until discharge. The postoperative chest drainage volume, postoperative bleeding, pulmonary embolism incidence, and respiratory complications were analyzed. RESULTS: (1) There were no significant differences in prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) between the pre-operation prophylactic anticoagulation group (PRE group) [(11.5±3.9) s, (27.8±3.5) s, (0.96±0.06) s] and the post-operation prophylactic anticoagulation group (POST group) [(11.4±1.4) s, (28.3±4.0) s, (0.98±0.07) s] (P=0.796, P=0.250, P=0.137), and there was no significant difference in Caprini score between the PRE group (3.1±1.8) and the POST group (3.3±1.5) (P=0.104). (2) There were no significant differences in anesthesia time and intraoperative bleeding between PRE group [(130.2±53.9) min, (76.8±49.3) mL] and POST group [(142.2±56.5) min, (73.7±41.6) mL] (P=0.067, P=0.201). (3) The total drainage volume in 72 hours after operation in PRE group [(728.1±505.7) mL] was significantly higher than that of POST group [(596.4±373.5) mL] (P=0.005), while there were no significant differences between the two groups in total postoperative drainage volume [(1, 066.8±1, 314.6) mL vs (907.8±999.8) mL, P=0.203]. (4) There were no significant differences between the two groups in pulmonary embolism incidence (1.785% vs 0.019%, P=0.525) and postoperative bleeding rates (1.785% vs 0.039%, P=0.300). (5) There were no significant differences between PRE group and POST group in subcutaneous emphysema incidence (1.785% vs 1.581%, P=0.989) and pulmonary infection rates (14.285% vs 6.324%, P=0.085). CONCLUSION: The clinical value of preoperative prophylactic anticoagulation is equal to postoperative prophylactic anticoagulation for lung cancer patients. 中国肺癌杂志编辑部 2018-10-20 /pmc/articles/PMC6189024/ /pubmed/30309428 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.06 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 胸外科围术期vte专题
肺癌患者围手术期预防性抗凝的临床价值分析
title 肺癌患者围手术期预防性抗凝的临床价值分析
title_full 肺癌患者围手术期预防性抗凝的临床价值分析
title_fullStr 肺癌患者围手术期预防性抗凝的临床价值分析
title_full_unstemmed 肺癌患者围手术期预防性抗凝的临床价值分析
title_short 肺癌患者围手术期预防性抗凝的临床价值分析
title_sort 肺癌患者围手术期预防性抗凝的临床价值分析
topic 胸外科围术期vte专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189024/
https://www.ncbi.nlm.nih.gov/pubmed/30309428
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.06
work_keys_str_mv AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī
AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī
AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī
AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī
AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī
AT fèiáihuànzhěwéishǒushùqīyùfángxìngkàngníngdelínchuángjiàzhífēnxī